Introduction and Exploring the Financial Burden of Follicular Lymphoma

Follicular lymphoma is often underrecognized not only for its clinical complexity but also for the significant financial strain it places on patients and the healthcare system. Its indolent yet incurable nature means patients frequently cycle through multiple lines of therapy over many years, accumulating substantial costs related to diagnostics, treatment, monitoring, and supportive care. Advanced therapies, while effective, can markedly increase out-of-pocket expenses, and the need for ongoing surveillance adds to cumulative financial stress. Indirect costs—such as missed work, caregiver responsibilities, and insurance navigation—further compound the burden. Because the disease may appear less urgent than aggressive lymphomas, the economic impact is sometimes underestimated. Improving awareness of these long-term financial challenges is essential to designing sustainable care pathways, optimizing resource allocation, and supporting patients throughout their treatment journey.